Granules India reports income from operations at Rs 1,030 crores up 29 per cent
YoY, EBITDA at Rs 193 crores, EBITDA margin at 19 per cent; PAT at Rs 111 crores
Granules India yesterday announced its financial results for the quarter and year ended 31st March, 2022. The Board of Directors have recommended final dividend of 75 paise per equity share of Re 1/- each in addition to interim dividend of 75 paise per equity share of Re 1/- each paid during the year, as per a company statement.
Further, the revenue for Q4FY22 stood at Rs 1,030 crores, growth of 29 per cent YoY across all geographies and segments. Revenue share from Europe increased to 21.5 per cent when compared to 14.5 per cent YoY, the statement said.
Apart from it, the company saw increase in revenue, EBITDA and PAT in Q4FY22 compared to Q3FY22, despite adverse business condition arising out of supply constraints of Para Amino Phenol (PAP), other input price cost increase and logistic cost increase, according to the statement.
Revenue share of non-core molecules stood at 19 per cent on a full-year basis versus 16 per cent in the previous year, in line with the company’s long-term strategy. During the quarter, Granules also filed one ANDA, two US DMF, and received two ANDA approvals, the statement concluded.